**8. Chemotherapy treatment and implants**

Systemic antineoplastic therapy includes induction, neoadjuvant, adjuvant, and palliative therapy [40]. The survival rate of osseointegrated implants in the patient with antineoplastic and antiangiogenic therapy has not yet been elucidated. Controlled animal studies have shown negative effects on the osseointegration process with chemotherapeutic regimens with cisplatin, bevacizumab and sunitinib [41–43]. However, retrospective studies in humans have reported that chemotherapy has no detrimental effects on the osseointegration and functional stability of dental implants. The success rates reported by these studies were 97.6 and 99.1% [44–46].
